Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Public ClinicalTrials.gov record NCT07007962. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.
Study identification
- NCT ID
- NCT07007962
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 23, 2025
- Primary completion
- Nov 4, 2027
- Completion
- Dec 29, 2028
- Last update posted
- Jun 21, 2026
2025 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Community Health Partners (CHP) - Community Medical Oncology Specialists (University Oncology Associates) | Clovis | California | 93611 | Recruiting |
| University of Southern California (USC) | Los Angeles | California | 90089 | Recruiting |
| Tulane University Health Sciences Center - Tulane Avenue-Investigational Site Number: 8400011 | New Orleans | Louisiana | 70112 | Recruiting |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Recruiting |
| Mass General Brigham Cancer Institute | Danvers | Massachusetts | 01923 | Recruiting |
| University of Michigan Health - Michigan Medicine - University Hospital-Investigational Site Number: 8400001 | Ann Arbor | Michigan | 48109 | Recruiting |
| Mayo Clinic_Investigational Site Number: 8400009 | Rochester | Minnesota | 55905 | Recruiting |
| New York Oncology Hematology-Investigational Site Number: 8400010 | Albany | New York | 12208 | Recruiting |
| Montefiore Medical Center-Investigational Site Number: 8400012 | The Bronx | New York | 10467 | Recruiting |
| Oregon Health and Sciences University | Portland | Oregon | 97239 | Recruiting |
| Community Cancer Trials of Utah-Investigational Site Number: 8400002 | Ogden | Utah | 84405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07007962, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07007962 live on ClinicalTrials.gov.